Quick Facts: Uses of SMOFKabiven-central

• Provides nutritional support when oral or tube feeding is not feasible.
• Intended for adults and children aged two years and above.
• Supplies calories, protein, and essential fatty acids to address nutritional requirements.

---

What SMOFKabiven-central Treats: Main Uses and Benefits

SMOFKabiven-central is an established treatment utilized to provide parenteral nutrition. The administration of this product is indicated for patients who require nutritional support when standard oral or enteral (tube) feeding methods are determined to be impossible, insufficient, or clinically inappropriate. This treatment serves to address the fundamental nutritional requirements of patients who cannot sustain adequate intake through the digestive system.

It is used to help maintain nutritional status and prevent conditions associated with insufficient intake of essential nutrients, such as negative nitrogen balance. It delivers a supply of amino acids (protein components), glucose (carbohydrates), and lipids (fats) to contribute to a patient's caloric and metabolic needs. SMOFKabiven-central is suitable for use in adults and pediatric patients from two years of age. Treatment implementation and adjustment must be conducted under the direction and supervision of a qualified healthcare professional, with dosing tailored to the individual's specific requirements and clinical presentation.

Who Can and Cannot Use SMOFKabiven-central

Eligibility for SMOFKabiven-central is strictly defined by regulatory authorities based on age, underlying medical conditions, and physiological stability. The solution is approved for use in adults, adolescents, and pediatric patients aged 2 years and above when oral or enteral nutrition is impossible or inadequate.

Contraindications and Restrictions

The medicine must not be used (is contraindicated) in patients with specific severe conditions:

• Hypersensitivity to fish, egg, soybean, or peanut protein, or to any component of the solution.
• Severe hyperlipidemia or uncontrolled hypertriglyceridemia.
• Severe organ failure, specifically severe liver insufficiency or severe renal insufficiency without access to dialysis.
• Uncontrolled metabolic states, including uncontrolled hyperglycemia or congenital errors of amino acid metabolism.
• Acute shock or other unstable, life-threatening conditions (e.g., severe blood coagulation disorders).

Age Restrictions: The product is not recommended for children under 2 years of age, as its fixed formulation does not meet the specific nutritional requirements of this younger group.

Pregnancy and Lactation: Use in pregnant or breastfeeding women is limited due to a lack of established data and should only be administered if deemed necessary by a healthcare professional.

Interactions with other medicines and products

The official regulatory documentation for this Total Parenteral Nutrition solution details specific interaction patterns, primarily concerning physical incompatibilities, required timing of administration, and metabolic effects.

Contraindicated and Restricted Combinations

Co-administration with the antibiotic Ceftriaxone is formally contraindicated in neonates (patients 28 days of age or younger) due to the documented risk of precipitation with the solution's calcium component. For all patients, simultaneous administration of Ceftriaxone via a Y-site connection is strictly prohibited. If these products must be given sequentially, the infusion line must be thoroughly flushed with a compatible fluid between administrations. Furthermore, this product must not be given simultaneously with blood in the same infusion set to avoid the risk of pseudoagglutination.

Pharmacodynamic and Metabolic Effects

The lipid component may affect the action of certain drugs. The anticoagulant activity of Coumarin derivatives, such as Warfarin, may be officially counteracted due to the presence of Vitamin K1 in the soybean oil. Regarding lipid metabolism, Heparin administration causes a transient release of lipoprotein lipase, resulting in a subsequent decrease in triglyceride clearance. Additionally, Insulin may officially interfere with the body's lipase system. It is also documented that the product’s circulating lipid content can interfere with the accuracy of certain laboratory measurements, such as bilirubin, if blood samples are taken before adequate lipid clearance.

How SMOFKabiven-central Works

SMOFKabiven-central is a Total Parenteral Nutrition product formulated to provide comprehensive macronutrients and micronutrients at a systemic level via central venous access. Its mechanism of action is primarily metabolic, involving the provision and utilization of essential cellular substrates.

---

Provision of Essential Energy Substrates

Glucose (dextrose) and the lipid emulsion components are metabolized via glycolysis, beta-oxidation, and the Krebs cycle to generate Adenosine Triphosphate (ATP). The metabolic utilization of these substrates contributes to cellular energy production required for metabolic processes.

---

Cellular and Tissue Maintenance

The amino acid component provides free amino acids that are rapidly incorporated into the body's free pool. These are utilized for protein synthesis (anabolism) at the cellular level, providing necessary components for structural and functional proteins.

---

Regulation of Cellular Processes and Cofactor Activity

Electrolytes maintain osmotic pressure and transmembrane potential necessary for cellular signaling. Vitamins and trace elements function as cofactors and antioxidants. These participate in various enzymatic reactions, maintain cellular membrane potential, and contribute to antioxidant defense mechanisms.

Administration Process

SMOFKabiven-central is an emulsion for infusion administered through a clinical process involving a dedicated intravenous access point. The preparation consists of a three-chamber bag system containing amino acids, electrolytes, lipids, and glucose. These components are kept separate until the point of use to maintain the stability of the mixture.

Preparation of the Bag

The infusion bag is enclosed in an overpouch that serves as a protective barrier. Before the procedure begins, the integrity of the bag and the appearance of the contents are verified. The emulsion is intended for single use and is prepared by breaking the peelable seals between the chambers, allowing the individual solutions to mix thoroughly into a homogenous white emulsion.

Method of Delivery

This specific formulation is designed for administration into a large central vein. The delivery is typically managed using an infusion pump to ensure a consistent and controlled flow rate over a set period. The duration of the infusion is usually extended over several hours, often spanning a significant portion of the day or night, depending on the clinical requirement for nutrient absorption.

Handling and Storage During Use

Once the seals are broken and the contents are mixed, the emulsion is typically used promptly. If the infusion is not started immediately, the mixture is stored under specific temperature-controlled conditions to prevent degradation. Any remaining portion of the emulsion after the infusion period is concluded is discarded according to standard clinical protocols.

Research Evidence / Overview of Studies

Clinical Trial Results Summary

Clinical trials have been conducted to evaluate the use of SMOFKabiven-central (a total parenteral nutrition formulation) in adult patients requiring nutritional support, particularly following surgery. The research assessed patient outcomes and nutritional status when compared to standard hospital-compounded parenteral nutrition (PN) admixtures.

I. Nutritional Status and Comparative Outcomes

Studies focused on demonstrating that SMOFKabiven was non-inferior (comparable) to traditional PN formulations. The primary outcome measure in key trials was the change in serum prealbumin levels from baseline, a common indicator of protein nutritional status. Data from randomized trials indicate that the change in prealbumin levels was comparable between the SMOFKabiven group and the control group, suggesting a similar effect on nutritional status during the study period.

Outcome Assessed	Finding in Key Comparative Trials (e.g., Post-Surgical)
Change in Prealbumin	Comparable to compounded PN admixtures
Omega-3 Fatty Acids (EPA/DHA)	Significantly higher levels observed with SMOFKabiven

II. Safety and Tolerability

Safety was evaluated by comparing the incidence of adverse events (AEs) between the two treatment groups. Treatment-related adverse events were generally comparable in frequency between SMOFKabiven and hospital-compounded PN. The research also compiled data on adverse event rates across different patient demographics and assessed the number of participants who discontinued treatment due to AEs.

Limitations and Ongoing Research

Current evidence remains limited in the long-term assessment of outcomes beyond the typical 5-to-7 day treatment period in acute care settings. Further research is underway to assess the effects of formulations with higher protein content, such as SMOFKabiven Extra Nitrogen, in critically ill patients, with endpoints including mean protein delivery, survival time, and ICU length of stay. These studies aim to ensure that nutritional targets can be met without increasing the risk of overfeeding with energy.

Common questions about SMOFKabiven-central (FAQ)

Q: Is SMOFKabiven-central a type of chemotherapy or cancer treatment?

A: This product is officially classified as a Total Parenteral Nutrition (TPN) solution, which is a specialized form of intravenous nutritional support. Regulatory documents indicate its purpose is to provide nutrients (fats, proteins, and sugars) when a patient cannot eat or absorb food, not as a chemotherapy agent. Nutritional support is often necessary for patients undergoing various treatments, including oncology care.

Q: Can taking SMOFKabiven-central cause weight gain?

A: The core function of this TPN solution is to supply the body with energy and building blocks necessary for cellular maintenance and protein synthesis (anabolism). While weight gain is not specifically listed as a common adverse reaction in official labeling, the product’s primary purpose is to meet metabolic and nutritional needs and prevent severe malnutrition.

Q: Is SMOFKabiven-central safe for older adults (seniors)?

A: Official documentation does not contain specific age-related precautions or required dose adjustments for older adults. The primary age restriction documented is only for pediatric patients under 2 years of age. Dosage is always customized based on the patient’s individual clinical condition and specific nutritional needs.

Q: Can you drive or operate machinery while receiving SMOFKabiven-central?

A: Regulatory documents include a section on the effects on the ability to drive and use machines. Since this product is typically administered in a controlled medical setting, official information states caution may be appropriate if any symptoms that affect concentration or reaction are experienced.

Q: Are there specific warnings for people with heart conditions?

A: Yes, official regulatory documents list severe conditions such as Cardiopulmonary instability, Acute shock, and Decompensated cardiac insufficiency as reasons why the product must not be used (contraindications). These warnings are related to the general risks of administering infusion therapy to patients with unstable heart or lung function.

Q: What are the signs of a potential overdose or getting too much?

A: An infusion rate that is too fast may result in a serious, officially documented adverse reaction known as Fat Overload Syndrome. General signs of receiving too much of the solution may include an abnormal increase in blood fat (triglyceride) levels, fever, shivering, vomiting, or breathing difficulty.

Q: What is the difference between SMOFKabiven-central and other Kabiven products?

A: The core difference lies in the lipid component (fats). SMOFKabiven-central contains a specific lipid emulsion called SMOFlipid, which is a blend of four different fat sources, including fish oil. This specific blend is the key distinguishing factor compared to other older Kabiven formulations that feature a different fat profile.

Q: Does SMOFKabiven-central come in other forms, like pills or liquid I can drink?

A: No. This product is strictly an emulsion for infusion designed to be delivered only through an intravenous line into a central vein. According to official product information, it is not available in oral forms, such as pills or liquid you can drink, because it is designed to bypass the digestive system entirely.

Q: Can diabetic patients use SMOFKabiven-central?

A: Use is contraindicated (must not be used) in patients with uncontrolled hyperglycemia (high blood sugar). Regulatory information indicates that patients with conditions like diabetes should have their metabolic status closely monitored for appropriate use.

Q: What is the typical duration of use for SMOFKabiven-central treatment?

A: The intended duration of use is generally considered short-term, such as during 5 to 7 days in post-surgical or acute care settings, as referenced in clinical trials. Official labeling warns that receiving parenteral nutrition for greater than 2 weeks increases the risk of certain complications, such as liver disease.

Q: Is there a generic version or an alternative to SMOFKabiven-central?

A: Regulatory documents indicate the product's effectiveness is comparable (non-inferior) to standard hospital-compounded parenteral nutrition (PN) admixtures. While no chemically equivalent generic version is noted, it is one of several types of PN solutions available for patients with compromised digestive function.

Q: Does SMOFKabiven-central make you feel hungry or affect appetite?

A: The official product label lists lack of appetite (anorexia) as an uncommon side effect. The overall purpose of the solution is to meet the body's full nutritional needs when oral intake is impossible or severely compromised.

Q: What is the long-term safety profile of this medication according to studies?

A: The official labeling carries a warning that the risk of Parenteral Nutrition-Associated Liver Disease (PNALD) is increased in patients who receive parenteral nutrition for greater than 2 weeks. Official labeling describes the need for monitoring of liver function for continuous use beyond this period.

Q: What happens if a bag is expired or damaged?

A: Official instructions indicate the bag should be discarded if it is expired, shows any evidence of damage, or if the seals are broken before mixing. The contents should also be discarded if the solution appears separated or abnormal after mixing.

Q: Does SMOFKabiven-central contain sodium or potassium?

A: Yes. The complete product formulation includes various essential electrolytes necessary for bodily function. Regulatory documentation confirms that components containing both sodium and potassium are included within the multi-chamber bag solution.

Q: How does the use of SMOFKabiven-central relate to hospital stays?

A: Regulatory documentation frequently discusses the product's use in critically ill patients, post-surgical patients, and patients in the intensive care unit (ICU) setting. This indicates that it is often initiated and administered in a controlled clinical environment during a hospital stay.

Q: Is it normal for the bag to look slightly cloudy or yellow?

A: No. The contents of the three chambers, once properly mixed, should result in a homogenous, white emulsion. Regulatory instructions caution that the bag should be discarded if the solution appears yellow or shows any signs of separation, such as yellowish streaking, as this indicates damage.

How to Store and Dispose of SMOFKabiven-central

The storage and disposal instructions for SMOFKabiven-central are designed to maintain its stability as a multi-chamber nutritional emulsion.

Storage Requirements

Condition	Unactivated Bag	Activated Admixture (Without Additives)
Temperature	Store below 25°C (77°F); Do not freeze.	Stable for 48 hours at 25°C or up to 7 days under refrigeration (2°C to 8°C).
Protection	Keep in the original container and protected from light.	If refrigerated, infuse within 48 hours of removal.

Disposal and Safety

The product must be kept out of the sight and reach of children. Any mixture remaining after infusion must be discarded. Disposal of unused product, expired product, or waste material must be carried out in accordance with local requirements for pharmaceutical waste. The bag must be discarded if damaged or if seals are broken prior to mixing.